KIBRA Attains Oncogenic Activity by Repressing RASSF1A

Show simple item record

dc.contributor.author Arivazhagan, A.L.
dc.contributor.author Surabhi, R.P.
dc.contributor.author Kanakarajan, A.
dc.contributor.author Sundaram, S.
dc.contributor.author Pitani, R.S.
dc.contributor.author Mudduwa, L.K.B.
dc.contributor.author Kremerskothen, J.
dc.contributor.author Venkatraman, G.
dc.contributor.author Rayala, S.K.
dc.date.accessioned 2024-09-19T03:46:47Z
dc.date.available 2024-09-19T03:46:47Z
dc.date.issued 2017-08-08
dc.identifier.citation Anuj, Arivazhagan L, Surabhi RP, Kanakarajan A, Sundaram S, Pitani RS, Mudduwa L, Kremerskothen J, Venkatraman G, Rayala SK. KIBRA attains oncogenic activity by repressing RASSF1A. Br J Cancer. 2017 Jun 29;117(4):553–62. doi: 10.1038/bjc.2017.192. Epub ahead of print. PMID: 28664913; PMCID: PMC5558681. en_US
dc.identifier.uri http://ir.lib.ruh.ac.lk/handle/iruor/17543
dc.description.abstract Background: KIBRA—initially identified as a neuronal associated protein is now shown to be functionally associated with other tissue types as well. KIBRA interacts with dyenin light chain 1 and this interaction is essential for oestrogen receptor transactivation in breast cancer cells. KIBRA as a substrate of Cdk1, Aurora kinase and ERK plays an important role in regulating cell cycle, cell proliferation and migration. Despite these evidences, the exact role of KIBRA in cancer progression is not known. Methods: We studied the expression of KIBRA in breast tissues and breast cancer cell lines by western blotting, immunohistochemisry (IHC) and RT-PCR. Stable over expression and knockdown clones were generated to study the transforming properties of KIBRA by conventional assays. Xenograft studies were performed in nude mice to study the in vivo tumourigenic efficacy of KIBRA. qPCR array was performed to understand the molecular mechanism behind oncogenic activity of KIBRA. Results: Our results showed that KIBRA is upregulated in breast cancer cells and in malignant human breast tumours by both western blotting and IHC. Interestingly, we found that KIBRA expression level goes up with increase in breast cancer progression in well-established MCF10A model system. Further, results from stable overexpression clones of KIBRA in fibroblasts (Rat-1) and epithelial breast cancer cells (ZR75) and lentiviral short hairpin RNA-mediated knockdown (KD) clones of KIBRA in ZR75 showed increase in transforming properties with KIBRA overexpression and vice-versa. Results also showed that fibroblasts stably overexpressing KIBRA showed increased tumourigenic potential in nude mice. By adopting a quantitative PCR array-based approach, we identified RASSF1A, a tumour suppressor, as a transcriptional target of KIBRA. Conclusions: This is the first study to demonstrate the in vivo tumourigenic property of KIBRA in a nude mouse model and also unravel the underlying molecular mechanism of KIBRA-mediated transformation via repression of RASSF1A. en_US
dc.language.iso en en_US
dc.publisher Springer en_US
dc.subject KIBRA en_US
dc.subject transformation en_US
dc.subject breast cancer en_US
dc.subject Rat-1 cells en_US
dc.subject RASSF1A en_US
dc.subject tumour xenografts en_US
dc.title KIBRA Attains Oncogenic Activity by Repressing RASSF1A en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account